Aditxt, Inc. Signs Letter of Intent for Exclusive Rights to Negotiate the Acquisition of a Biopharmaceutical Company Commercializing and Distributing Antiviral Oral Therapy for COVID-19
Aditxt (ADTX) has signed a letter of intent to acquire a biopharmaceutical company focused on COVID-19 antiviral oral therapy, which is commercially available in multiple international markets. The transaction includes a proposed $6.5M secured loan from Aditxt to the target company, with shares issued representing 50% of Aditxt’s outstanding shares post-closing. Completion of the acquisition is contingent on various conditions, including due diligence and shareholder approval, with an exclusivity period ending on September 30, 2021.
- Strategic expansion into the COVID-19 oral antiviral market.
- Potential to enhance Aditxt's global operational footprint in Europe, Asia, and the Middle East.
- Expected synergies with Aditxt’s existing immune system technologies.
- Acquisition completion is subject to numerous conditions, creating uncertainty in the deal.
- Potential shareholder dilution due to the issuance of additional shares.
Target Acquisition Has Operational and Sales Footprint in
The acquisition is subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive agreements and other closing conditions, including board and shareholder approval and approval by Nasdaq of the listing of shares proposed to be issued in the transaction. The parties have agreed to an exclusivity period until
Key terms of the proposed transaction as stated in the LOI include: the completion of a proposed
“We have been eager to grow the global footprint of Aditxt’s immune therapeutic and monitoring platforms," said
About
Forward-Looking Statements
Certain statements in this press release constitute “forward-looking statements” within the meaning of federal securities laws. Forward looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company’s ongoing and planned product and business development; the Company’s intellectual property position; the Company’s ability to develop commercial functions; expectations regarding product launch and revenue; the Company’s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005485/en/
Media and Investor Relations Contact:
Chief Communications Officer
ir@aditxt.com
Source:
FAQ
What is Aditxt's recent acquisition about?
What are the terms of the acquisition by Aditxt?
When is the exclusivity period for Aditxt's acquisition deal?
What markets does the target company operate in?